<DOC>
	<DOCNO>NCT00471653</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient receive temozolomide may help doctor learn temozolomide work body . It may also help doctor learn patient 's gene may affect risk develop thrombocytopenia . PURPOSE : This clinical trial study pharmacokinetics patient newly diagnose high-grade glioma receive temozolomide radiation therapy .</brief_summary>
	<brief_title>Pharmacokinetics Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Compare pharmacokinetic ( PK ) profile temozolomide ( TMZ ) patient develop severe thrombocytopenia v PK profile patient develop severe thrombocytopenia receive standard first-line therapy management newly diagnose high-grade glioma . - Determine patient develop thrombocytopenia single nucleotide polymorphism O6-methylguanine-DNA methyltransferase gene . OUTLINE : This pilot , prospective , multicenter study . Patients receive oral temozolomide daily day 1-42 . Patients also undergo cranial radiotherapy 5 day week 6 week absence disease progression unacceptable toxicity . Blood sample collect periodically pharmacokinetic pharmacogenomic analysis , genotype analysis , plasma temozolomide level , MGMT repair gene polymorphism analysis . After completion study treatment , patient follow 1 month . PROJECTED ACCRUAL : A total 150 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highgrade glioma ( WHO grade III IV ) Must schedule receive standard firstline therapy ( cranial radiotherapy temozolomide ) PATIENT CHARACTERISTICS : ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.7 mg/dL Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 4 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except curatively treat carcinoma situ basal cell carcinoma skin PRIOR CONCURRENT THERAPY : No prior hormonal therapy brain tumor No prior biological agent ( include immunotoxins , immunoconjugates , antisense agent , peptide receptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte , lymphokineactivated killer cell , gene therapy ) No prior immunotherapy No prior chemotherapy No prior radiotherapy , include cranial radiotherapy Concurrent glucocorticoid therapy allow No concurrent carbamazepine No concurrent experimental therapy No concurrent cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>thrombocytopenia</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>